Please tell us about your experience. How many patients with high triglycerides and high cholesterol do you treat?

How much do you believe the recent FDA’s invalid due to obviousness ruling on Amarin’s patents for Vascepa will affect the prescriptions from now on?

What are some of the ex-U.S. potential barriers to generic competition?

Considering generics are not yet approved and penalties for at-risk generic launches remain, how much do you feel Vascepa will keep its appeal to clinicians and patients?

If Amarin were to enter into settlements with generic companies for Vascepa in the U.S., would that change your impression on the drug or the company in any meaningful way?

In a recent data release, Serum EPA Levels were reported at 400% Increase and DHA levels showed a decrease of 2.9%, Following Administration of VASCEPA. Can you walk us through the importance of this data point?

What can you tell us related to the cost-effectiveness study? How much do patients have to pay, on average, and how would that change in the event of generic competition?